Trial Profile
A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Atrasentan (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics; Therapeutic Use
- 09 Nov 2005 New trial record.